P-Value Workshop
19 Dec 2025
Brussels, 19 December 2025
On 9 December, EORTC hosted the second P-value Workshop, and welcomed over 250 participants online from over 43 countries.
The workshop, marking 100 years of the 5% p-value cutoff, was a great opportunity to exchange views on how we define scientific evidence today. Discussions highlighted the continued relevance of p-values, while also emphasising the need to avoid relying on them in isolation.
Speakers and participants explored how decision-making in clinical research should be informed by a balanced assessment of benefits and risks, supported by reliable estimates, and how future guidelines could help shape a more nuanced and meaningful approach to evidence-based research.
The discussions were insightful and engaging. A big thank you to our speakers for their valuable contributions, and to everyone who joined and shared their perspectives. A full report will be shared in due course capturing the key insights from these conversations.
Related News
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
EORTC Imaging Group Becomes the Diagnostic and Therapeutic Imaging Group
24 Apr 2026
Investing in the future of cancer research; EORTC’s Young and Early Career investigator Network shows its value
23 Apr 2026
In Memoriam of Martine Van Glabbeke (1951-2026)
17 Apr 2026
PEACE-3 trial demonstrates significant overall survival benefit in patients with metastatic castration-resistant prostate cancer with bone metastases
27 Feb 2026
EORTC celebrates Rare Disease Day: Addressing unmet needs in rare cancers
27 Feb 2026
First Site Activated in EORTC RENALUT Clinical Trial on Metastatic Clear Cell Renal Cell Carcinoma
26 Feb 2026
World Cancer Day: How clinical cancer research changes lives
4 Feb 2026
